Adult

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

Retrieved on: 
Tuesday, November 14, 2023
CNS, Research, Bone marrow, SAN, OGM, University, Hospital, Scalability, B-cell lymphoma, Expo Hall, Genomics, Second Level Address Translation, CD5, Laboratory, Neoplasm, Crocker, Ravindra and Smita Kolhe, Workflow, DSM-IV codes, SVS, Convention center, Greater Columbus Convention Center, Cancer, Mapping, Central nervous system, MD Anderson Cancer Center, AMP, Medical device, Vaccine, DRS, Adult, Brigham

AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.

Key Points: 
  • AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.
  • The presenters will share data on OGM’s performance in this research application as compared to traditional cytogenetic methods of analysis, including microarrays.
  • Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies.
  • In addition, 19 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, November 13, 2023
WFIA, Safety, Exercise, Psych, Patient, ADHD, Series, Cingulata, Dietary supplement, Security (finance), Adult, AISRS

KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update.

Key Points: 
  • If results from this study are successful, pivotal Phase 3 clinical trials in all patient segments for CTx-1302 are expected to begin in 2025.
  • Cash Position: As of September 30, 2023, Cingulate had $2.0 million in cash and cash equivalents.
  • Cingulate expects its cash and cash equivalents will enable the Company to fund its research and development and operating expenditures through mid-November 2023.
  • Net loss was $16.6 million for the nine months ended September 30, 2023, compared to $13.0 million for the same period in 2022.

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Retrieved on: 
Sunday, December 10, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, HIV, ASH, Patient, TI, FDA, Quality of life, Betibeglogene autotemcel, Thalassemia, Bleeding, TDT, Transfusion-dependent anemia, Society, Medical device, Pharmaceutical industry, Adult

As of the data cutoff date, TI was maintained through last follow-up (up to 6 years) across ages and genotypes.

Key Points: 
  • As of the data cutoff date, TI was maintained through last follow-up (up to 6 years) across ages and genotypes.
  • Among patients in the Phase 1/2 studies, 68.2% (15/22) achieved TI, with 14 patients sustaining TI through the last follow-up (up to 9 years).
  • The patient continued to benefit from beti-cell therapy and was not receiving chronic red blood cells transfusions as of the last follow-up.
  • The most common beti-cel-related AEs (occurring in ≥3 patients) were abdominal pain (7.9% of patients) and thrombocytopenia (4.8% of patients).

Global Compounding Pharmacies Market Research Report 2023-2030: Analysis by Therapeutic Area, Age Cohort, Compounding Type, and Sterility - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
Health, Pharmaceutical, Pediatrics, Medicine, Conditional sentence, PIA, Allergy, Pain management, Patient, FDA, USD, Prescription, COVID-19, PDA, Growth, Human, Pharmacy, CQA, Dietary supplement, Pharmaceutical industry, Adult, Dermatology

The "Compounding Pharmacies Market Size, Share & Trends Analysis Report By Therapeutic Area (Specialty Drugs, Dermatology), By Age Cohort (Pediatric, Adult), By Compounding Type (PIA, PDA), By Sterility, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Compounding Pharmacies Market Size, Share & Trends Analysis Report By Therapeutic Area (Specialty Drugs, Dermatology), By Age Cohort (Pediatric, Adult), By Compounding Type (PIA, PDA), By Sterility, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global compounding pharmacies market size is expected to reach USD 18.6 billion by 2030.
  • It is projected to register a CAGR of 5.11%
    The market's growth can be attributed to the growing importance of medication adherence and increasing supportive government policies.
  • Compounding pharmacies specialize in creating customized medications based on the unique needs of individual patients.

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adolescence, Safety, CAH, Investment, PD, Administration, Patient, Public expenditure, Androstenedione, G&A, Pharmacokinetics, PCOS, A4, R, Research and development, Pharmaceutical industry, Nursing, Cryptocurrency, Adult

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
  • CAHmelia-203 Study in Adult Classic CAH Completes Target Enrollment: Target enrollment of 72 patients in the company’s CAHmelia-203 clinical trial is complete .
  • Due to substantial patient interest in CAHmelia-203, final enrollment in the study will exceed its original target of 72 patients.
  • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of September 30, 2023 were $108.0 million.

CPRWrap™ Included in Tory Burch Foundation's Exclusive Holiday Gift Guide

Retrieved on: 
Tuesday, December 5, 2023
Woman, Tory Burch, Life, Amazon, BIPOC, Language, CPR, Infant, Walmart, Education, Tourism, Online shopping, Adult, Child

HIXSON, Tenn., Dec. 4, 2023 /PRNewswire-PRWeb/ -- CPRWrap™, a compact, life-saving tool that ensures you're always prepared to perform CPR swiftly, announces its inclusion in the Tory Burch Foundation 2023 Holiday Gift Guide. A simple-to-use product that addresses the problem of decreased bystander intervention during CPR, CPRWrap™ is featured alongside over 200 women-owned brands.

Key Points: 
  • HIXSON, Tenn., Dec. 4, 2023 /PRNewswire-PRWeb/ -- CPRWrap™ , a compact, life-saving tool that ensures you're always prepared to perform CPR swiftly, announces its inclusion in the Tory Burch Foundation 2023 Holiday Gift Guide .
  • "As a woman-owned BIPOC business, the support I have received from the Tory Burch Foundation is without question the most impactful for my business' success," said Jackson.
  • "Whether you're giving it as a stocking stuffer or receiving one, CPRWrap might be the most meaningful gift you ever exchange."
  • Felicia Jackson , CPRWrap™ inventor and founder, is part of the exclusive Tory Burch Foundation community, a nonprofit founded by designer and entrepreneur Tory Burch to empower women founders.

THE OMNI GROVE PARK INN UNVEILS WINNERS OF THE 31st ANNUAL NATIONAL GINGERBREAD HOUSE COMPETITION

Retrieved on: 
Tuesday, November 21, 2023
The Sundays, Blue Ridge Rollergirls, Tongkonan, The People's Choice, Biltmore Estate, Classical, Fiddlehead, How to Cake It, Christmas, Ingredient, Courtland High School, Tub, Love, Diner, FOX, Partnership, The Great Hall, Visions of Sugar Plums, Holiday, Crime Scene Kitchen, Creativity, Edible, Tree, Great hall, Stable, Nightclub, Auction, Film industry, Toy, Restaurant, Amusement park, Adult, Child

ASHEVILLE, N.C., Nov. 21, 2023 /PRNewswire/ -- The Omni Grove Park Inn held its highly anticipated Annual National Gingerbread House Competition™, yesterday which included 200 entries from over 22 states and Guatemala. Contestants spanned across adult, teen, youth and children categories all competing for a chance to win a piece of more than $40,000 in cash and prizes.

Key Points: 
  • ASHEVILLE, N.C., Nov. 21, 2023 /PRNewswire/ -- The Omni Grove Park Inn held its highly anticipated Annual National Gingerbread House Competition™ , yesterday which included 200 entries from over 22 states and Guatemala.
  • The furthest traveled competitor was Beatriz Mejia who traveled 4,234 miles from Guatemala to participate in this year's competition.
  • For more information on The Omni Grove Park Inn, call (800) 438-5800 or visit omnihotels.com/hotels/asheville-grove-park .
  • For more information on The 31st Annual National Gingerbread House Competition™, call (800) 413-5778 or visit omnihotels.com/gingerbread .

The Inner Circle Acknowledges, Sandra Chamberlain as a Pinnacle Life Member for her contributions to the field of Technology

Retrieved on: 
Monday, November 13, 2023
Online, Inner circle, University at Buffalo, Bangladesh Technical Education Board, Woman, Economics, MCC, Education, Palo Alto, California, Naturalization, Language, ACS, Virtual campus, Disability, Student, Monroe Community College, Mentorship, Culture, Royal, Army, Vietnam Children's Fund, University, Family, Publishing, Dream, Military personnel, Integration, Volunteering, Master, Nursing, Tutoring, Kaiserslautern, Adult, Geology

ROCHESTER, N.Y., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sandra Chamberlain is acknowledged as a Pinnacle Life Member for her contributions to the field of Technology.

Key Points: 
  • ROCHESTER, N.Y., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sandra Chamberlain is acknowledged as a Pinnacle Life Member for her contributions to the field of Technology.
  • Mrs. Chamberlain pursued higher education, first earning a Bachelor of Science degree in Geology from the University of Wisconsin-Eau Claire.
  • After graduating from UW-EC, she flew to California, where she applied for and accepted a job at the U.S. Geological Survey in Menlo Park, California.
  • She loved the opportunity, and it was also during this time she met her husband, Royal, who went to the heavenly realm in December 2021.

H&H Group posts solid Q3 revenue growth, fuelled by nutritional supplements category

Retrieved on: 
Thursday, November 2, 2023
BNC, Yoy, LFL, IMF, H&H, Hill's Pet Nutrition, Trust, ANC, Growth, Breast milk, LPN, PNC, Adult

As I take the helm of H&H into its next exciting chapter focused on growth, global expansion, and innovation - I'm encouraged by what I see.

Key Points: 
  • As I take the helm of H&H into its next exciting chapter focused on growth, global expansion, and innovation - I'm encouraged by what I see.
  • The Group has been strategically enhancing the international footprint of its IMF business by launching innovative products to build recognition and trust.
  • This quarter, H&H rolled out 'Inostime' in France - a game-changing IMF series enriched with Lactopontin (LPN), a crucial component of breast milk.
  • This positions the Group to achieve solid topline growth throughout 2023.

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Retrieved on: 
Friday, November 3, 2023
FDA, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Patient, University of Milan, Society, Poster, ASH, Efficacy, Corporation, University, Abstract, Dentistry, Hematology, Adult

Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.
  • Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
  • The report was authored by an external group of investigators involved in the treatment of these patients with narsoplimab provided under Omeros’ compassionate use program.
  • Details of the presentation are as follows:
    Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience (Abstract #3543)